Verrica Pharmaceuticals Announces Executive and Board Changes

Ticker: VRCA · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1660334

Verrica Pharmaceuticals Inc. 8-K Filing Summary
FieldDetail
CompanyVerrica Pharmaceuticals Inc. (VRCA)
Form Type8-K
Filed DateSep 27, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-appointment

TL;DR

Verrica Pharma shakes up leadership: new CMO appointed, two new directors join the board.

AI Summary

Verrica Pharmaceuticals Inc. announced on September 23, 2024, changes in its executive and director roles. The company appointed Dr. Robert L. W. Smith as Chief Medical Officer and elected Dr. Paul J. G. Mann and Ms. Sarah E. Kelly to its Board of Directors.

Why It Matters

These leadership changes could signal a shift in strategic direction or focus for Verrica Pharmaceuticals, potentially impacting its drug development and commercialization efforts.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and operational execution.

Key Players & Entities

  • Verrica Pharmaceuticals Inc. (company) — Registrant
  • Dr. Robert L. W. Smith (person) — Appointed Chief Medical Officer
  • Dr. Paul J. G. Mann (person) — Elected to Board of Directors
  • Ms. Sarah E. Kelly (person) — Elected to Board of Directors
  • September 23, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Robert L. W. Smith has been appointed as the new Chief Medical Officer.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on September 23, 2024.

Who were elected to the Board of Directors?

Dr. Paul J. G. Mann and Ms. Sarah E. Kelly were elected to the Board of Directors.

What is Verrica Pharmaceuticals Inc.'s state of incorporation?

Verrica Pharmaceuticals Inc. is incorporated in Delaware.

What is the principal executive office address for Verrica Pharmaceuticals Inc.?

The principal executive office address is 44 W. Gay St., Suite 400, West Chester, PA 19380.

Filing Stats: 391 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2024-09-27 16:15:59

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: September 27, 2024 /s/ Ted White Ted White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.